Health Condition 1: M259- Joint disorder, unspecified
Conditions
Interventions
Intervention1: Ropivacaine with Magnesium Sulphate: Ropivacaine (0.5%) combined with Magnesium Sulphate (50 mg) administered for postoperative analgesia in a peripheral nerve stimulator-guided supracl
Sponsors
Datta Meghe Institute of Medical Sciences Sawangi Meghe Wardha
Eligibility
Inclusion criteria
Inclusion criteria: Patients undergoing upper limb surgeries requiring supraclavicular plexus block. American Society of Anesthesiologists (ASA) Physical Status I and II. Willing to provide written informed consent. Body mass index (BMI) within the range of 18 30 kg/m .
Exclusion criteria
Exclusion criteria: Patients with known hypersensitivity to Ropivacaine, Magnesium Sulphate, or local anesthetics. History of coagulopathy or bleeding disorders. Presence of infection at the injection site. Patients with severe systemic diseases (e.g., ASA Physical Status III and above). Neurological or psychiatric disorders affecting pain perception. Pregnant or lactating women. Patients on chronic opioid therapy or magnesium supplements. Refusal to consent to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Duration of postoperative analgesia, measured as the time from administration of the supraclavicular plexus block to the first request for rescue analgesia.Timepoint: 2 years | — |
Secondary
| Measure | Time frame |
|---|---|
| Pain intensity, assessed using the Visual Analog Scale (VAS) at 2, 4, 6, 12, and 24 hours postoperatively.Timepoint: Evaluated at 2, 4, 6, 12, and 24 hours postoperatively. | — |
Countries
India
Contacts
Public ContactKaruna Taksande
Datta Meghe Institute of Higher Education and Research
Outcome results
None listed